<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04632277</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-2019-01-407</org_study_id>
    <nct_id>NCT04632277</nct_id>
  </id_info>
  <brief_title>Is Mg do Improve the Glycemic Control in Patients Drink a Desalinate Water</brief_title>
  <acronym>Mg</acronym>
  <official_title>Daily Intake of Magnesium From Drinking Water in Relation to Diabetes Mellites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imam Abdulrahman Bin Faisal University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Saline Water Conversion Corporation Research Institute at Al-Jubail, KSA.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imam Abdulrahman Bin Faisal University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and aim:&#xD;
&#xD;
      Diabetes mellitus as a chronic disease is on rise on parallel with diseases. Magnesium (Mg)&#xD;
      supplementation may help control glycemic response among type 2 diabetes (T2D) patients. We&#xD;
      aim to present an overview of the possible influence of drinking water in general and mineral&#xD;
      water in particular in improving glycemic parameters in persons with type 2 diabetes.&#xD;
&#xD;
      Method:&#xD;
&#xD;
      A randomized double blind controlled clinical trial will be conducted at the Endocrine clinic&#xD;
      (KFHU) on 900 of patients with T2DM. All subjects participated in this study will be randomly&#xD;
      allotted into three groups (each group N=300) to which the three waters were supplied in&#xD;
      similar bottles marked A &quot;tap water&quot;, B &quot;bottle water&quot; and C &quot;control without any&#xD;
      intervention&quot;.&#xD;
&#xD;
      Blood samples will be taken before and after the intervention to determine the serum&#xD;
      concentration of magnesium, Calcium, Vit D, creatinine, FBS, serum Ca, HbA1c, fasting&#xD;
      C-peptide levels, fasting insulin levels and insulin sensitivity. Magnesium and calcium&#xD;
      levels in urine will be expressed as the creatinine ratio&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study population and design:&#xD;
&#xD;
      A randomized double blind controlled clinical trial will be conducted at the Endocrine clinic&#xD;
      (KFHU) on 900 of patients with T2DM. This sample size was calculated at confidence interval&#xD;
      of 95%. for the total diabetic outpatients in Endocrine clinic at KFHU during the period&#xD;
      October 2020-May 2021.&#xD;
&#xD;
      All subjects living in the 3 catchment areas (Dammam. Khobar and Dhahran) in the eastern&#xD;
      province before inclusion were selected.&#xD;
&#xD;
      Intervention All subjects participated in this study will be randomly (double-blind) allotted&#xD;
      into three groups (each group N=300) to which the three waters were supplied in similar&#xD;
      bottles marked A &quot;tap water&quot;, B &quot;Low Mg bottle water (50mg/l)&quot; and C &quot; high Mg bottle water&#xD;
      (100 mg/l)&quot;. These doses have been chosen according to the guideline of WHO.&#xD;
&#xD;
      All patients will be asked to consume at least one liter of water/day. When preparing coffee&#xD;
      and tea, ordinary tap water could be used. The intervention will be lasted for lasted 3&#xD;
      months. None of the participants will be changed their normal dietary habits during the&#xD;
      trial.&#xD;
&#xD;
      The mean values of all the studied parameters will be checked before starting the protocol&#xD;
      for standardization of the protocol situp of the participants. Moreover, the diary magnesium&#xD;
      intake will be calculated by a dietitian and all the influential factors such as, demographic&#xD;
      factors, baseline 25(OH)D, Vit D and calcium intake, Oestrogen use and sun exposure will be&#xD;
      controlled and monitored during the research.&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
      All patients with type 2 on any diabetic treatment aged 20-85 years old with hypomagnesemia&#xD;
      (less than 0.6 mmol/L (1.46 mg/dL).&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
      Type 1 diabetic patients, pregnant women, patients who use of immunosuppressive,&#xD;
      corticosteroids, and non-steroidal anti-inflammatory, patients who have renal dysfunction or&#xD;
      doing dialysis,&#xD;
&#xD;
      Sampling and data collection:&#xD;
&#xD;
      All participants will be seated in air-conditioned rooms and had 10-15 min of rest before&#xD;
      measurements were taken. After signing the consent form, the demographic and clinical data of&#xD;
      all subjects will be record including: address, education level, smoking, age, sex; and body&#xD;
      weight and height were measured to calculate body mass index (BMI). The average of three&#xD;
      consecutive blood pressure readings with intervals of 5-min rest will be obtained, using an&#xD;
      electronic sphygmomanometer. All measurements and indicators will be taken at the base line&#xD;
      and after three months of intervention.&#xD;
&#xD;
      Blood and urine samples Blood samples will be taken before and after the intervention to&#xD;
      determine the serum concentration of serum magnesium, Calcium, Phosphorus, Vit D, creatinine,&#xD;
      Urea, Lipid profile, Uric acid, Liver function test, Fasting blood glucose, HbA1c, fasting&#xD;
      C-peptide levels, fasting insulin levels and insulin sensitivity. The HOMA-IR will be&#xD;
      calculated according to the following formulas: HOMA-IR = (glucose mg x insulin level)/405.&#xD;
      Blood samples will be collected before and after the intervention period. A sample of urine&#xD;
      will be collected to measure Microalbuminuria. The analysis will be performed at the central&#xD;
      laboratory, KFHU.&#xD;
&#xD;
      Research ethics:&#xD;
&#xD;
      Ethical approved and performed under the guideline of the research ethics committee of Imam&#xD;
      Abdulrahman Bin Faisal University, Saudi Arabia and written consent will be obtained from all&#xD;
      subjects.&#xD;
&#xD;
      Statistical analysis:&#xD;
&#xD;
      The data was entered into an SPSS. The data analysis will be divided into two steps:&#xD;
      Descriptive statistics and analysis of variance. The quantitative data will be represented in&#xD;
      the form of proportions (%) and of means with standard deviations. The one-way ANOVA will be&#xD;
      used to measure the changes between groups.&#xD;
&#xD;
      Funds details:&#xD;
&#xD;
      This project will be supported by The Saline Water Conversion Corporation Research Institute&#xD;
      at Al-Jubail, KSA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 25, 2020</start_date>
  <completion_date type="Actual">August 1, 2021</completion_date>
  <primary_completion_date type="Actual">May 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Magnesium (Mg).</measure>
    <time_frame>3 months</time_frame>
    <description>Serum Mg mg/dL. Baseline and 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting blood glucose</measure>
    <time_frame>3 months</time_frame>
    <description>Fasting blood glucose mg/dL. Baseline and 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin μIU/mL</measure>
    <time_frame>3 months</time_frame>
    <description>Serum Insulin μIU/mL. Baseline and 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>3 months</time_frame>
    <description>HbA1c. Baseline and 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum HDL (high-density lipoprotein)</measure>
    <time_frame>3 months</time_frame>
    <description>Serum HDL mg/dL. Baseline and 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum LDL (low-density lipoprotein)</measure>
    <time_frame>3 months</time_frame>
    <description>Serum LDL mg/dL. Baseline and 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Triglycerides</measure>
    <time_frame>3 months</time_frame>
    <description>Serum Triglycerides mg/dL. Baseline and 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Cholesterol</measure>
    <time_frame>3 months</time_frame>
    <description>Serum Cholesterol mg/dL. Baseline and 3 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Calcium</measure>
    <time_frame>3 months</time_frame>
    <description>Ca md/dL. Baseline and 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Microalbumin</measure>
    <time_frame>3 months</time_frame>
    <description>microalbuminurea (30-300 mcg/mg creatinine). Baseline and 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Vitamin D</measure>
    <time_frame>3 months</time_frame>
    <description>Vit D ng/mL. Baseline and 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Urea mg/dL</measure>
    <time_frame>3 months</time_frame>
    <description>Baseline and 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine.</measure>
    <time_frame>3 months</time_frame>
    <description>Baseline and 3 months (mg/dL)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Body weight</measure>
    <time_frame>3 months</time_frame>
    <description>weight in kilograms. Baseline and 3 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Body height</measure>
    <time_frame>3 months</time_frame>
    <description>height in meters. Baseline and 3 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Body mass index</measure>
    <time_frame>3 months</time_frame>
    <description>Weight in kilograms divided by the square of height in meters. Baseline and 3 months</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Patients</condition>
  <condition>Glucose, High Blood</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A &quot;tap water&quot;,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expermental recieve low MG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Mg bottle water (50mg/l)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expermental recieve high MG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high Mg bottle water (100 mg/l)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Water</intervention_name>
    <description>Participants will receive a tab water</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Water with low Mg</intervention_name>
    <description>Participants will receive Low Mg bottle water (50mg/l)</description>
    <arm_group_label>Expermental recieve low MG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Water with high Mg</intervention_name>
    <description>Participants will receive High Mg bottle water (100mg/l)</description>
    <arm_group_label>Expermental recieve high MG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients with type 2&#xD;
&#xD;
          -  On any diabetic treatment&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Type 1 diabetic Delete repeated word&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Patients who use of immunosuppressive, corticosteroids, and non-steroidal&#xD;
             anti-inflammatory.&#xD;
&#xD;
          -  Patients who have renal dysfunction or doing dialysis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mtalhariri@Iau.Edu.Sa</name>
      <address>
        <city>Dammam</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Fahd Hospital of the University</name>
      <address>
        <city>Khobar</city>
        <zip>2208</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <reference>
    <citation>Barbagallo M, Dominguez LJ, Galioto A, Ferlisi A, Cani C, Malfa L, Pineo A, Busardo' A, Paolisso G. Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X. Mol Aspects Med. 2003 Feb-Jun;24(1-3):39-52. Review.</citation>
    <PMID>12537988</PMID>
  </reference>
  <reference>
    <citation>Larsson SC, Wolk A. Magnesium intake and risk of type 2 diabetes: a meta-analysis. J Intern Med. 2007 Aug;262(2):208-14. Review.</citation>
    <PMID>17645588</PMID>
  </reference>
  <results_reference>
    <citation>Murakami S, Goto Y, Ito K, Hayasaka S, Kurihara S, Soga T, Tomita M, Fukuda S. The Consumption of Bicarbonate-Rich Mineral Water Improves Glycemic Control. Evid Based Complement Alternat Med. 2015;2015:824395. doi: 10.1155/2015/824395. Epub 2015 Dec 21.</citation>
    <PMID>26798400</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Imam Abdulrahman Bin Faisal University</investigator_affiliation>
    <investigator_full_name>MOHAMMED ALHARIRI</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Magnesium</keyword>
  <keyword>Diabetes mellitus</keyword>
  <keyword>Blood samples</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>No plan to share the results</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

